Shanghai Zhangjiang promotes the specialization of biomedical industry, builds Tianci sharing platform, addresses the "last mile" of the industrialization of innovative drugs, greatly improves the efficiency of pharmaceutical production capacity, reduces the comprehensive cost of the industry, and sets up the brand of “Zhangjiang medicine” in the international market.
At present, Zhangjiang Hi-Tech Park signed a number of major projects. Shanghai Tianci International Pharmaceuticals Co., Ltd. signed cooperation agreements with Fosun Kite Biotechnology Co., Ltd. and Shanghai Green Valley Pharmaceutical Co., Ltd. respectively, which marked the official completion of industrialization of two major domestic innovative drugs in Zhangjiang Hi-Tech Park.
According to this cooperation agreement, two original innovative drugs, Yescarta, a new drug of Fosun Kate, and sodium oligo-mannurarate capsules (GV971), developed by Green Valley Pharmaceutical, will be officially launched on the sharing pharmaceutical platform of Tianci International for production and come in the market fully. This cooperation also means that Tianci International, the first domestic sharing pharmaceutical platform, has officially put into operation.
After more than 20 years of development, Zhangjiang has always assumed the mission of national new drug R & D. At present, Zhangjiang has become a symbolic science and technology park with rich R&D resources, rapid growth in the number of innovative achievements and the first breakthrough of new technologies and new models. Zhangjiang is home to China's highest level of new drug projects and technological talents. Therefore, Zhangjiang is known as the "China’s Medicine Valley".
In recent years, Zhangjiang's innovative medicine achievements are mushrooming, indicating that this innovative fertile soil has entered the harvest season. The products of Fosun Kate and Green Valley are the first ripe fruits. But with so many new drugs coming out, how can Zhangjiang guarantee the production of original and innovative drugs when the production resources are very scarce? How can it transform "Zhangjiang R&D" into "Zhangjiang Intelligent Manufacturing"? How can it gradually develop the cost center of pharmaceutical R&D into the profit center of Chinese innovative enterprises?
In order to overcome these difficulties through the market-oriented innovation model, Tianci International has made innovations, broken the traditional barriers of interests, and created a sharing pharmaceutical platform that meets the needs of the new era. Under the guidance of the national drug Marketing Authorization Holder (MAH) policy, Tianci International has built a “Science & Innovation Dream Works” through many years of hardships, which will be put into production.
Located in the south of Zhangjiang Hi-Tech Park and covering 211 mu and a construction area of 280,000 square meters, Tianci “Science & Innovation Dream Works” has 20 standard workshops and can undertake 80 GMP production lines at most. As Zhangjiang is known as "China Pharmaceutical Valley", this base will strongly support Zhangjiang's biomedical innovation chain as a functional platform for the transformation of Zhangjiang's biomedical achievements. Tianci International integrates R&D, production and sales resources to form a "flexible, open and giving" sharing platform and address the last mile, namely the industrialization of innovative medicine. Yescarta and GV971 are the first contracted cooperation projects of Tianci International. In the future, more original innovative drugs will be manufactured in Science & Innovation Dream Works.
Li Hanpu, Chairman of Tianci International, said, "Science & Innovation Dream Works differs greatly from the traditional pharmaceutical factory in concept and mode. As we all know, new drugs are all found under the stages of drug discovery, preclinical research, clinical research, production, commercialization and so on; every new drug cannot be marketed without the support of pharmaceutical factories. Traditional pharmaceutical factories are more insular, often only producing their own drugs without any social service and creativity, thus failing to innovate mostly. In view of these disadvantages, Tianci innovatively creates a world-class sharing pharmaceutical platform, which not only greatly improves the pharmaceutical productivity efficiency and remarkably reduces the overall cost of the industry, but also improves the transformation rate of innovative R&D results.” She also said that Tianci International relied on Zhangjiang's innovative resources to elaborately build a new biomedical ecological chain, including pharmaceutical production services, clinical research services, drug sales services, drug registration services and financial services. The industry chain has solved the biggest pain point in the current biomedical industry.
Tang Shiqing, director of the Science, Technology and Economic Commission of Shanghai Pudong New Area, said that after more than 20 years of development, Zhangjiang's biomedical industry has entered a mature stage. It is not only ranked the first in China, but also world-renowned in the field of medical research and development. However, for a long time, Zhangjiang has focused on the ability of research and development of biomedicine, but neglects the ability of production and manufacturing.
Tang Shiqing said, “The innovative development of Tianci sharing pharmaceutical platform reflects many Zhangjiang's ideas and innovations for the next round of energy level upgrading of biomedical industry. It can be said that the emergence of this new platform pioneering in China has made Zhangjiang biomedical industry form a real closed loop, thus supporting the birth of a new era and legend of Zhangjiang pharmaceutical industry.”
He pointed out that Zhangjiang has established a public research and development platform, experimental verification platform and academic resource platform for biomedicine. From the point of view of the complete value chain, it only lacks a sharing production platform. Therefore, the Tianci innovative platform fills this gap, and the market-based investment model determines its strong vitality and competitiveness in the future.
Tang Shiqing said, "The biomedical industry has its particularity. It needs not only the promotion of star enterprises, but also the support of the integrity of the industry. The attempt and innovation of Tianci sharing platform is conducive to Zhangjiang pharmaceutical industry from the innovation chain to the value chain. It plays a decisive role in the positive fund withdrawal of innovative enterprises and the subsequent R&D upgrading."
He also said that in the future, government departments will focus on and support this innovative platform, and comprehensively improve the level of government services and promote the professional capacity building of the entire industry. Not only will the use of Tianci sharing platform greatly reduce the financial pressure of R&D team, but also the use of the professional capacity of sharing production platform to improve quality management and cost control, so that "Zhangjiang Medicine", the brand is really going on all over the world, bringing new drugs "Made in Shanghai" to the world.
Tianci sharing pharmaceutical platform has addressed the last mile of transformation of scientific and technological achievements of new drugs. In view of the shortcomings and pain points of Zhangjiang's innovative drugs, a perfect transformation professional platform has been constructed to better transform scientific and technological achievements into real productive forces. In the future, Shanghai will not only be the "origin" of innovative drugs, but also create the whole industry chain ecology of innovative drugs.
